Business Wire

EUNETWORKS

31.12.2020 11:08:17 CET | Business Wire | Press release

Share
euNetworks Acquires The Loop Manchester

euNetworks Fiber UK Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has acquired 100% of the shares of The Loop Manchester Limited (“The Loop”), from Gamma Telecom Holdings Limited (“Gamma”). The Loop is a duct and sub-duct based fibre network in Greater Manchester in the United Kingdom.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201231005050/en/

The Loop launched in 2012 and has a unique duct network stretching more than 87km across the key commercial areas of Manchester, Salford and Trafford. With over 180km of high capacity fibre cables, it connects into 20 data centres, two Exchanges and provides high capacity internet into more than 70 key multi-tenant commercial buildings. Approximately 48km of the duct network is entirely unique routing from alternative operators in the city. That routing combined with 700 chambers and expansion capability, offers a strong compliment to euNetworks current fibre network in Manchester. As well as serving the growing Manchester media sector, The Loop’s customers include major data centre operators, enterprises and public sector organisations.

euNetworks is focused on delivering high bandwidth fibre connectivity between and within cities in Europe. The company owns and operates deep fibre networks in 17 cities, including Manchester, and also operates a highly differentiated long haul network that spans 15 countries. euNetworks continues to invest in its network, building unique routes, adding multiple diverse paths and extending reach into key hyperscale data centre sites, data centre clusters and network aggregation points. These investments continue to fuel the company’s growth and are driven by the capacity requirements of euNetworks’ customers. At the heart of this is the company’s direct, diverse connectivity to over 440 data centres across Western Europe.

“Manchester is an important and growing digital hub and we have been keen to develop our presence in the city for some time. It also enhances our Super Highway that runs from Dublin through to Manchester, London and Lowestoft,” said Brady Rafuse, Chief Executive Officer of euNetworks. “The acquisition of The Loop network strengthens our customer proposition in the bandwidth infrastructure market. As well as adding unique routes to our Manchester metro, the Loop provides us with a more local presence, the flexibility to connect more data centres and buildings and the opportunity for further expansion. Prior to this acquisition, our Manchester metro consisted of 42km of duct network, 276 chambers and direct connection into 17 data centres. The combined footprint will deliver immediate value to both existing customers and our new customers that we welcome from The Loop.”

Andrew Taylor, Gamma’s Chief Executive Officer, commented: “We have developed The Loop into a successful and growing business which is now ready for its next phase and we’re really pleased that euNetworks has chosen to be its ensuing owner. euNetworks’ extensive fibre footprint across Europe and the UK coupled with their customer centred approach to network development and investment is both impressive and innovative.”

“This is a great match for The Loop and we are delighted to have been acquired by euNetworks and to be joining the team,” said Ashley Griffiths, Managing Director of The Loop. “We’ve worked closely with euNetworks for a number of years in Manchester and I know our customers will immediately benefit from this acquisition. We remain focused on delivering a great service experience as well as more fibre-based service options to our customers.”

“We anticipate a rapid integration of The Loop into euNetworks,” added Rafuse. “We are delighted to welcome Ashley and the team into the euNetworks group along with their customers and suppliers. Their local knowledge, expertise, impressive development and strong relationships in the market are invaluable as we look to grow euNetworks’ presence in the region. In addition, our focus on the media sector is immediately strengthened with their knowledge and strong reputation among the media and broadcast community in Manchester and the UK. There’s a great opportunity from the teams and the networks coming together to develop and future-proof some of the larger content requirements of these companies.”

About euNetworks

euNetworks is a bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 51 cities in 15 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 440 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com .

About Gamma

Gamma is a leading supplier of Unified Communications as a Service (UCaaS) in the UK, German, Spanish and Dutch business markets. It is AIM listed and employs 1450 people. With a range of UCaaS, Mobile and Connectivity services, Gamma provides robust and secure solutions that enable organisations to communicate, collaborate and offer a better customer experience. Gamma focuses its family of businesses on digital automation, delivering UCaaS services to SME customers largely via a network of channel partners. For further information visit www.gammacommunicationsplc.com

About The Loop Manchester Ltd

The Loop Manchester is more than 180km of fibre network, supplying direct connectivity to data centres and ultrafast internet access to the private and public sector. The network stretches across Salford, Trafford and the city of Manchester. For further information visit https://www.theloopmanchester.co.uk/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye